Online citations, reference lists, and bibliographies.
← Back to Search

Utility Of Osteopontin And Serum Mesothelin In Malignant Pleural Mesothelioma Diagnosis And Prognosis Assessment

B. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, M. Grégoire, H. Porte, M. Copin, P. Lassalle
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Purpose: Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment. We compared diagnostic and prognostic values of mesothelin and osteopontin in 172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects. Experimental Design: Osteopontin and mesothelin were assayed with commercial ELISA kits in a series of 43 patients with pleural metastases of various carcinomas, 33 patients with benign pleural lesions associated with asbestos exposure, 96 patients with MPMs, and 112 asbestos-exposed healthy subjects. Results were correlated with patient's diagnosis and survival. Results: Serum osteopontin level was higher in MPM patients compared with healthy asbestos-exposed subjects and had a good capability to distinguish between these two populations. However, osteopontin was unable to distinguish between MPM and pleural metastatic carcinoma or benign pleural lesions associated with asbestos exposure. Neither plasma nor pleural fluid osteopontin were more powerful in this respect. Serum mesothelin had a good ability for diagnosing MPM but was unable to identify patients with nonepithelioid mesothelioma subtypes. Survival analysis identified tumor histologic subtype along with serum osteopontin and serum mesothelin as independent prognostic factors in mesothelioma patients. Conclusions: Osteopontin has a lower diagnostic accuracy than mesothelin in patients suspected of MPM. Insufficient specificity limits osteopontin utility as diagnostic marker. Both molecules have a potential value as prognostic markers.
This paper references
The role of osteopontin in lung disease.
A. O’Regan (2003)
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
Prog - nostic significance of osteopontin expression in early - stage non - small - cell lung cancer
L Boldrini (2005)
Asbestos exposure and serum osteopontin.
A. Hiraki (2006)
Rusch VW; from the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma
Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.
S. Ashkar (2000)
Cutpoint determination methods in survival analysis using SAS R
MandrekarJN (1999)
Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer.
S. de Silva Rudland (2006)
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
sociation of S 100 A 4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer
S deSilvaRudland (2006)
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.
D. Agrawal (2002)
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
Application of mesothelin immunos - taining in tumor diagnosis
N Scholler (2003)
Asbestos exposure and serum osteopontin.
A. O’Regan (2006)
A method of comparing the areas under receiver operating characteristic curves derived from the same cases.
J. Hanley (1983)
Transformed mammalian cells secrete specific proteins and phosphoproteins
D. Senger (1979)
Serum osteopontin levels--is it time to screen asbestos-exposed workers for pleural mesothelioma?
M. Cullen (2005)
Osteopontin as a potential diagnostic biomarker for ovarian cancer.
J. Kim (2002)
Clin Cancer Res Bogdan-Dragos Grigoriu
Soluble mesothelin-related protein in the diagnosis of malignant pleural mesothelioma
A. Scherpereel (2006)
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.
A. Bhattacharjee (2001)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
An application of change - pointmethods in studying the effect of age on survival in breast cancer
C Contal (1983)
Osteopontin: a key cytokine in cell‐mediated and granulomatous inflammation
A. O’Regan (2000)
Osteopontin: possible role in prostate cancer progression.
G. Thalmann (1999)
Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker
I. Hellstrom (2006)
Osteopon - tin : possible role in prostate cancer progression
GN Thalmann (1999)
Quantifi - cationof osteopontin inhumanplasmawith an ELISA : basal levels in pre - and postmenopausal women
DS Bautista (1996)
Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
M. Onda (2006)
The role of Osteopontin in tumor metastasis.
P. Wai (2004)
Role of osteopontin in tumour progression
S. R. Rittling (2004)
Osteopontin expression in lung cancer.
A. Chambers (1996)
Pathology of malignant mesothelioma
R. Attanoos (1997)
Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions
A. Kolb (2005)
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer
L. Boldrini (2005)
Cutpoint determination methods in survival analysis using SASR
Mandrekar Mandrekarjn
Novel ELISA system for detection of N‐ERC/mesothelin in the sera of mesothelioma patients
K. Shiomi (2006)
Osteopontin expression and distribution in human carcinomas.
L. F. Brown (1994)
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
Osteo - pontin expression and prognostic significance in non - small cell lung cancer
DonatiV (2005)
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
N. Fedarko (2001)
American Association for Cancer Downloaded from
Clinical Significance of Osteopontin in Esophageal Squamous Cell Carcinoma: Comparison with Common Tumor Markers
Y. Shimada (2005)
High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis.
Y. Koguchi (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Mesothelin Is Shed from Tumor Cells
M. Ho (2006)
Expression of osteopontin and HGF/Met in adult soft tissue tumors
V. Bramwell (2005)
secrete specific proteins and phospho - proteins
K Chang (1979)
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
Analysis of covariance using the rank transformation.
W. J. Conover (1982)
Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non–Small Cell Lung Cancer
Z. Hu (2005)
Mesothelinfamily proteins and diagnosis ofmesothelioma
BW Robinson (2003)
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
An application of changepoint methods in studying the effect of age on survival in breast cancer
C. Contal (1999)
Pathology of malignant mesothelioma.
E. V. Van marck (2004)
Transformedmam - malian
DR Senger (2004)
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
Detection and quantitation of serum mesothelin , a tumor marker for patients with mesothelioma and ovarian cancer
R Hassan (2006)
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women.
D. Bautista (1996)
Osteo - pontin expression in
AF Chambers (1994)
Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung Cancer
V. Donati (2005)

This paper is referenced by
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
A. Linton (2014)
Mechanisms of TRAIL resistance
N. Kumar (2018)
Pairon Cancers respiratoires professionnels
J. Pairon (2008)
- 1-Comparisons and combinations of the five tumor markers for mesothelioma : NERC / mesothelin , osteopontin , hyaluronic acid , CA 125 , and CYFRA 21-1
K. Shiomi (2011)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure.
K. Vyskočilová (2015)
Malignant pleural mesothelioma.
D. Ettinger (2012)
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Takayuki Muraoka (2013)
Translational advances in pleural malignancies
Georgios T. Stathopoulos (2011)
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
Asbestos-Related Diseases and Blood Biomarkers
A. Franko (2019)
Diagnostic et bilan du mésothéliome pleural malin
X. Dhalluin (2009)
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
B. Grigoriu (2009)
A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.
O. Melaiu (2012)
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
E. Park (2012)
Prognostic factors in malignant pleural mesothelioma.
B. Davidson (2015)
Biomarkers in mesothelioma
D. Arnold (2018)
Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
S. Watzka (2011)
Cancers respiratoires professionnels
J. Pairon (2008)
Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
L. Rojas (2019)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
Clinical Significance of SerumMesothelin in Patients with Mesothelioma and Lung Cancer
Alfonso Cristaudo (2007)
Osteopontin Levels in an Asbestos-Exposed Population
E. Park (2009)
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
Filip Mundt (2013)
Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome
Serena Lacerenza (2020)
Atteinte maligne de la plèvre
Xavier Dhalluin (2009)
Asbestos and its substitutes: International coordination and independent research needed -
S. Jargin (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar